Title: Abiraterone and increased survival in metastatic prostate cancer
Authors: de Bono, Johann S ×
Logothetis, Christopher J
Molina, Arturo
Fizazi, Karim
North, Scott
Chu, Luis
Chi, Kim N
Jones, Robert J
Goodman, Oscar B
Saad, Fred
Staffurth, John N
Mainwaring, Paul
Harland, Stephen
Flaig, Thomas W
Hutson, Thomas E
Cheng, Tina
Patterson, Helen
Hainsworth, John D
Ryan, Charles J
Sternberg, Cora N
Ellard, Susan L
Fléchon, Aude
Saleh, Mansoor
Scholz, Mark
Efstathiou, Eleni
Zivi, Andrea
Bianchini, Diletta
Loriot, Yohann
Chieffo, Nicole
Kheoh, Thian
Haqq, Christopher M
Scher, Howard I
COU-AA-301 Investigators
Contributors: Sch√∂ffski, Patrick
Issue Date: May-2011
Series Title: New England Journal of Medicine vol:364 issue:21 pages:1995-2005
Abstract: Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy.
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science